Table 6. Results of logistic regression analysis for responses to CPS.
| Variable | Univariate | Multivariate* | ||
|---|---|---|---|---|
| OR (95% CI) | P | OR (95% CI) | P | |
| Age (year) | 0.998 (0.977–1.020) | 0.889 | ||
| Sex (male) | 0.596 (0.319–1.114) | 0.105 | ||
| CKD stage | 0.661 | |||
| Stage 2 | Reference | |||
| Stage 3 | 1.509 (0.282–8.060) | 0.630 | ||
| Stage 4 | 1.061 (0.200–5.637) | 0.945 | ||
| Stage 5 | 0.939 (0.165–5.362) | 0.944 | ||
| eGFR (mL/min/1.73 m2) | 1.007 (0.988–1.028) | 0.465 | ||
| Basal serum potassium (mmol/L) | 4.048 (1.499–10.936) | 0.006 | 3.649 (1.217–10.941) | 0.021 |
| CPS formula (Kalimate®) | 1.638 (0.872–3.079) | 0.125 | ||
| Daily CPS dose (g/d) | 1.594 (1.000–2.540) | 0.050 | 1.228 (0.742–2.031) | 0.424 |
| ACEI/ARB | 0.458 (0.230–0.909) | 0.026 | 0.456 (0.226–0.919) | 0.028 |
OR, odds ratio; CI, confidence interval; CKD, chronic kidney disease; eGFR, estimated glomerular filtration rate; CPS, calcium polystyrene sulfonate; ACEI, angiotensin converting enzyme inhibitor; ARB, angiotensin II receptor blockade.
*Logistic regression analyses entering variables with P < 0.05 in univariate analysis.